Pharmaceutical Management of the COVID-19 Pandemic in Switzerland Public Health Authorities


Dr Josiane Tinguely Casserini

CAS Medicines and Medical Devices in Emergency and Disaster



Background

The COVID-19 pandemic reached Switzerland with the first patient in the canton Ticino on February 25th, 2020.





Survey

Method


- Electronic survey by survey monkey with data collection from 20 July to mid September 2020
- overview of actions undertaken and challenges experienced Swiss public health authorities
- Questionnaire to all cantonal doctors / pharmacists and federal authorities (FONES, FOPH and Swissmedic)
- 31 (54%) of 61 surveys were answered: 76% German, 24% French
- Investigators:
 - J. Tinguely Casserini, L. Schumacher, P. Bonnabry and N. Widmer



Legal basis

 For 40% of the respondent authorities, the entry the COVID-19 ordonnance 2 was fast enough

• 35% desired a listing of the changes






Results

Pandemic plan

Management of the crisis

100% of federal
authorities prepared an
internal pandemic plan,
67% of the cantonal
authorities used an
internal pandemic plan

70% have planned a business continuity plan



Human resources management in COVID-19

100% KAZs , 86% KAPs
and 43% of federal
authorities lack of human
resources:
59% did not have
employees, that dropped
out.
41% had only 1-5
employees that got ill.





PPE management in COVID-19

Professional expertise was not frequently enough consulted during the purchase of PPE in first wave:

- 60% of national partner (Swissmedic)
- 20% No vs. 55% Yes in case of cantonal partner

Disinfectant management in COVID-19

> **72%** of KAPs and respondents were satisfied with the ordonnance BBI 2020 1561

Planning reliability of disinfectant of Clariant:

100% 80% 60% 40% 26,32 % 31,58 % 20% 0% Yes No iden'i know

Oxygen management in COVID-19

81% checked on a shortage of oxygen

38% recalled packages 50% of cantons kept reserves of a certain oxygen quantity 25% increased manufacturing capacities



Actions to anticipate drug shortage

- Distribution controlled by supplier 50%
- Promotion of alternative therapies 43%
- Additional purchases 36%



Allocation of drugs in COVID-19

Allocation of hydroxychloroquine and lopinavir/ritonavir by the KSD/SSC/SANKO was just in time for 57%


FACULTY OF SCIENCES INSTITUTE OF PHARMACEUTIC

No problems Additional purchase ahead of time Distribution controlled via suppliers Expansion of production capacities promoted Import from other countries Promotion of other drugs with adjustment of therapy recommendations



Preparation for pandemic

How did you anticipate these bottlenecks in general?







Lessons learnt and discussion

- The culture of discussion built up over the years helped in the rapid implementation of measures.
- Regarding medical devices, substantial know-how had to be gathered first, even if there were authorities with the necessary knowledge.
- Active information is important (requested by 75% of authorities)
- Authorities with internal pandemic plan reacted faster and were more agile.
- We have to be prepared for future zoonoses and other pandemic emergencies.
- Exercise scenarios and rolling federal stocks are proposed.

